ARTICLE | Company News
BioTransplant, Catholic University of Louvain antibodies, autoimmune/inflammation, transplant news
April 7, 2003 7:00 AM UTC
The parties settled their licensing dispute related to a 1993 deal under which the university granted BTRN exclusive rights to develop and market BTI-322, a rodent monoclonal antibody. As settled, BTR...